These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 24760541)

  • 1. Treatment of osteogenesis imperfecta in adults.
    Lindahl K; Langdahl B; Ljunggren Ö; Kindmark A
    Eur J Endocrinol; 2014 Aug; 171(2):R79-90. PubMed ID: 24760541
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Approach to the Patient: Pharmacological Therapies for Fracture Risk Reduction in Adults With Osteogenesis Imperfecta.
    Liu W; Lee B; Nagamani SCS; Nicol L; Rauch F; Rush ET; Sutton VR; Orwoll E
    J Clin Endocrinol Metab; 2023 Jun; 108(7):1787-1796. PubMed ID: 36658750
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravenous pamidronate in osteogenesis imperfecta type VII.
    Cheung MS; Glorieux FH; Rauch F
    Calcif Tissue Int; 2009 Mar; 84(3):203-9. PubMed ID: 19137231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Oesteogenesis imperfecta--genetics, diagnosis and medical treatment].
    Brixen KT; Illum NO; Hansen B; Lund AM; Mosekilde L
    Ugeskr Laeger; 2007 Jan; 169(1):30-4. PubMed ID: 17217883
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Scoliosis in osteogenesis imperfecta caused by COL1A1/COL1A2 mutations - genotype-phenotype correlations and effect of bisphosphonate treatment.
    Sato A; Ouellet J; Muneta T; Glorieux FH; Rauch F
    Bone; 2016 May; 86():53-7. PubMed ID: 26927310
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Osteogenesis imperfecta in children and adolescents-new developments in diagnosis and treatment.
    Trejo P; Rauch F
    Osteoporos Int; 2016 Dec; 27(12):3427-3437. PubMed ID: 27492436
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Osteogenesis imperfecta: from diagnosis and multidisciplinary treatment to future perspectives.
    Bregou Bourgeois A; Aubry-Rozier B; Bonafé L; Laurent-Applegate L; Pioletti DP; Zambelli PY
    Swiss Med Wkly; 2016; 146():w14322. PubMed ID: 27346233
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Filling the gaps: osteogenesis imperfecta.
    Graul AI
    Drug News Perspect; 2005; 18(6):400-1. PubMed ID: 16247517
    [No Abstract]   [Full Text] [Related]  

  • 9. Bisphosphonate treatment of children and adults with osteogenesis imperfecta: unanswered questions.
    Brizola E; Shapiro JR
    Calcif Tissue Int; 2015 Aug; 97(2):101-3. PubMed ID: 26071113
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of atypical femoral fracture in a patient with osteogenesis imperfecta.
    Tan JY; Seow CJ
    BMJ Case Rep; 2017 Dec; 2017():. PubMed ID: 29269360
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship of Pathogenic Mutations and Responses to Zoledronic Acid in a Cohort of Osteogenesis Imperfecta Children.
    Sun L; Hu J; Liu J; Zhang Q; Wang O; Jiang Y; Xia W; Xing X; Li M
    J Clin Endocrinol Metab; 2022 Aug; 107(9):2571-2579. PubMed ID: 35727737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Update on the evaluation and treatment of osteogenesis imperfecta.
    Harrington J; Sochett E; Howard A
    Pediatr Clin North Am; 2014 Dec; 61(6):1243-57. PubMed ID: 25439022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravenous pamidronate treatment of children under 36 months of age with osteogenesis imperfecta.
    DiMeglio LA; Ford L; McClintock C; Peacock M
    Bone; 2004 Nov; 35(5):1038-45. PubMed ID: 15542028
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement.
    Letocha AD; Cintas HL; Troendle JF; Reynolds JC; Cann CE; Chernoff EJ; Hill SC; Gerber LH; Marini JC
    J Bone Miner Res; 2005 Jun; 20(6):977-86. PubMed ID: 15883638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravenous neridronate in adults with osteogenesis imperfecta.
    Adami S; Gatti D; Colapietro F; Fracassi E; Braga V; Rossini M; Tatò L
    J Bone Miner Res; 2003 Jan; 18(1):126-30. PubMed ID: 12510813
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum Sclerostin Levels in Adults With Osteogenesis Imperfecta: Comparison With Normal Individuals and Response to Teriparatide Therapy.
    Nicol L; Wang Y; Smith R; Sloan J; Nagamani SC; Shapiro J; Lee B; Orwoll E
    J Bone Miner Res; 2018 Feb; 33(2):307-315. PubMed ID: 29044725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bisphosphonates for the prevention of fractures in osteogenesis imperfecta: meta-analysis of placebo-controlled trials.
    Hald JD; Evangelou E; Langdahl BL; Ralston SH
    J Bone Miner Res; 2015 May; 30(5):929-33. PubMed ID: 25407702
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alendronate treatment in children with osteogenesis imperfecta.
    Akcay T; Turan S; Guran T; Bereket A
    Indian Pediatr; 2008 Feb; 45(2):105-9. PubMed ID: 18310788
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bone mineral density and fracture rate in response to intravenous and oral bisphosphonates in adult osteogenesis imperfecta.
    Shapiro JR; Thompson CB; Wu Y; Nunes M; Gillen C
    Calcif Tissue Int; 2010 Aug; 87(2):120-9. PubMed ID: 20544187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Osteogenesis imperfecta: practical treatment guidelines.
    Antoniazzi F; Mottes M; Fraschini P; Brunelli PC; Tatò L
    Paediatr Drugs; 2000; 2(6):465-88. PubMed ID: 11127846
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.